{"id":"seroquel-quetiapine","safety":{"commonSideEffects":[{"rate":"18-27%","effect":"Somnolence/sedation"},{"rate":"9-16%","effect":"Dry mouth"},{"rate":"10-18%","effect":"Dizziness"},{"rate":"5-23%","effect":"Weight gain"},{"rate":"13-19%","effect":"Headache"},{"rate":"8-10%","effect":"Constipation"},{"rate":"6-8%","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL3188993","moleculeType":"Small molecule","molecularWeight":"883.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which are implicated in psychosis and mood dysregulation. It also has activity at other receptors including alpha-adrenergic and histamine receptors, contributing to its sedating properties and broader psychiatric effects.","oneSentence":"Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:28.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania and maintenance)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04115319","phase":"PHASE3","title":"A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-11-21","conditions":"Schizophrenia","enrollment":305},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT05590637","phase":"PHASE4","title":"Comparing Antipsychotic Medications in LBD Over Time","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-04-22","conditions":"Parkinson's Disease Psychosis, Dementia With Lewy Bodies","enrollment":94},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT06333990","phase":"PHASE3","title":"Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)","status":"RECRUITING","sponsor":"Foundation for Advancing Veterans' Health Research","startDate":"2024-07-09","conditions":"Mild Traumatic Brain Injury","enrollment":146},{"nctId":"NCT03449472","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Quetiapine","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2018-01-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT06062953","phase":"PHASE2, PHASE3","title":"Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia","status":"RECRUITING","sponsor":"Lone Baandrup","startDate":"2023-09-18","conditions":"Psychiatric Disorders, Insomnia","enrollment":255},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT04521478","phase":"PHASE2","title":"A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-11-20","conditions":"Depressive Disorder, Major","enrollment":389},{"nctId":"NCT04950868","phase":"PHASE1","title":"The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verinder Sharma","startDate":"2022-03-18","conditions":"Postpartum Depression","enrollment":22},{"nctId":"NCT02958800","phase":"NA","title":"Deprescribing Antipsychotics in Long-Term Care","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-12","conditions":"Dementia, Behavior","enrollment":6},{"nctId":"NCT01737268","phase":"PHASE3","title":"Long-term Study of FK949E in Elderly Bipolar Disorder Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10-29","conditions":"Bipolar Disorder, Elderly","enrollment":20},{"nctId":"NCT01725308","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-02-07","conditions":"Bipolar Disorder","enrollment":431},{"nctId":"NCT02362412","phase":"PHASE3","title":"Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-02-18","conditions":"Bipolar Depression","enrollment":22},{"nctId":"NCT01725282","phase":"PHASE2","title":"Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-12-14","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT03403790","phase":"","title":"A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2018-01-15","conditions":"Depression, Bipolar Disorder","enrollment":369},{"nctId":"NCT06546358","phase":"EARLY_PHASE1","title":"Quetiapine Versus Trazadone in Women With Postpartum Depression","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-09","conditions":"Postpartum Depression","enrollment":50},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT05307003","phase":"","title":"Trazodone vs. Quetiapine for the Treatment of ICU Delirium","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2023-04-01","conditions":"Delirium, Delirium of Mixed Origin, Delirium, Sepsis Associated","enrollment":60},{"nctId":"NCT05085808","phase":"PHASE4","title":"RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)","status":"NOT_YET_RECRUITING","sponsor":"University of Southern California","startDate":"2025-03-01","conditions":"Delirium, Morality, Quality of Life","enrollment":30},{"nctId":"NCT00232336","phase":"PHASE4","title":"Quetiapine for Cocaine Use and Cravings","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2003-10","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":42},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT06200584","phase":"NA","title":"Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics","status":"COMPLETED","sponsor":"Dr Rabia Arshad","startDate":"2021-01-01","conditions":"Antipsychotics and Neuroleptics Toxicity","enrollment":140},{"nctId":"NCT04936126","phase":"PHASE4","title":"Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2021-08-07","conditions":"Treatment Resistant Depression","enrollment":150},{"nctId":"NCT05840861","phase":"","title":"Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders","status":"UNKNOWN","sponsor":"Central South University","startDate":"2020-11-05","conditions":"Major Depressive Disorder, Bipolar Disorder","enrollment":59},{"nctId":"NCT01342380","phase":"","title":"Pioglitazone and Quetiapine XR Pharmacogenetic Study","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-02","conditions":"Bipolar Disorder, Major Depressive Disorder","enrollment":42},{"nctId":"NCT05793632","phase":"PHASE2","title":"Quetiapine in Prevention of Delirium","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-03-01","conditions":"Delirium","enrollment":90},{"nctId":"NCT05303935","phase":"PHASE2","title":"Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Flinders University","startDate":"2022-05-25","conditions":"Sleep Apnea, Obstructive","enrollment":15},{"nctId":"NCT04728581","phase":"NA","title":"Improving Sleep After TKA Using Mirtazapine and Quetiapine","status":"NOT_YET_RECRUITING","sponsor":"St. Anna Ziekenhuis, Geldrop, Netherlands","startDate":"2024-01-01","conditions":"Osteo Arthritis Knee, Insomnia","enrollment":165},{"nctId":"NCT04280965","phase":"EARLY_PHASE1","title":"Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-02-01","conditions":"Post Traumatic Stress Disorder","enrollment":28},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT05801289","phase":"NA","title":"Quetiapine as Prophylaxis for Delirium in CABG","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-12-04","conditions":"Delirium","enrollment":60},{"nctId":"NCT04513314","phase":"PHASE4","title":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2023-03-28","conditions":"Covid19, Hyperactive Delirium, Pneumonia, Viral","enrollment":""},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT01858948","phase":"PHASE3","title":"SGA-induced Metabolic Syndrome in Bipolar Youth","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-07","conditions":"Bipolar Youth Treated With Second-generation Antipsychotics","enrollment":19},{"nctId":"NCT05480150","phase":"NA","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-01","conditions":"Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic","enrollment":10000},{"nctId":"NCT02978534","phase":"","title":"Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-03","conditions":"Bipolar Disorder","enrollment":4},{"nctId":"NCT02845453","phase":"PHASE4","title":"Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-01-20","conditions":"Substance Use Disorders, Bipolar Disorder, Mood Disorders","enrollment":24},{"nctId":"NCT05240261","phase":"PHASE1","title":"Sleep Disorders in Chronic Kidney Disease Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-05-01","conditions":"Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT05098353","phase":"NA","title":"Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control","status":"UNKNOWN","sponsor":"Federal Stare Budgetary Scientific Institution, Mental Health Research Center","startDate":"2021-04-10","conditions":"Bipolar Affective Disorder","enrollment":30},{"nctId":"NCT04164758","phase":"PHASE2","title":"Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine","status":"TERMINATED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2019-10-23","conditions":"Parkinson's Disease","enrollment":11},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT02467933","phase":"NA","title":"The Effect of Informative Letters on the Prescription and Receipt of Seroquel","status":"COMPLETED","sponsor":"Abdul Latif Jameel Poverty Action Lab","startDate":"2015-04","conditions":"Economics, Fraud, Delivery of Health Care","enrollment":5055},{"nctId":"NCT00406315","phase":"PHASE4","title":"Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":255},{"nctId":"NCT03004521","phase":"PHASE4","title":"Lithium Versus Quetiapine in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"King's College London","startDate":"2016-11","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":276},{"nctId":"NCT00159770","phase":"PHASE3","title":"Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-11","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":290},{"nctId":"NCT00370500","phase":"PHASE4","title":"Quetiapine and the Dopaminergic Epigenetic Control","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2007-04","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT03872596","phase":"PHASE1","title":"Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-03-27","conditions":"Bipolar Disorder, Schizophrenia","enrollment":58},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT01588457","phase":"PHASE4","title":"Sequential Multiple Assignment Treatment for Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-06","conditions":"Bipolar I Disorder, Bipolar II Disorder","enrollment":112},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT03572257","phase":"PHASE2, PHASE3","title":"Quetiapine Treatment for Pediatric Delirium","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2019-04-15","conditions":"Delirium","enrollment":""},{"nctId":"NCT03007303","phase":"","title":"The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients","status":"UNKNOWN","sponsor":"Dalian Seventh People's Hospital","startDate":"2016-06","conditions":"Schizophrenia, Micrognathia","enrollment":30},{"nctId":"NCT03207438","phase":"PHASE4","title":"Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2006-04","conditions":"Depressive Disorder, Major","enrollment":1790},{"nctId":"NCT00292370","phase":"PHASE4","title":"Quetiapine Augmentation for Treatment-resistant PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2006-01","conditions":"Combat Disorders, Stress Disorders, Post-Traumatic","enrollment":124},{"nctId":"NCT02087631","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Quetiapine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2014-12","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT00515723","phase":"NA","title":"Glucose and Lipid Metabolism on Antipsychotic Medication","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2001-09","conditions":"Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus","enrollment":96},{"nctId":"NCT02901587","phase":"PHASE1","title":"Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":119},{"nctId":"NCT00397020","phase":"PHASE4","title":"Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-12","conditions":"Bipolar Disorder","enrollment":30},{"nctId":"NCT00161018","phase":"PHASE3","title":"New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02720198","phase":"PHASE3","title":"Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-01-23","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT00457366","phase":"PHASE4","title":"A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2006-05","conditions":"Agitation","enrollment":72},{"nctId":"NCT00518973","phase":"NA","title":"Trial of Quetiapine in Anorexia Nervosa","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-07","conditions":"Anorexia Nervosa","enrollment":21},{"nctId":"NCT00954681","phase":"PHASE2","title":"Study of Quetiapine Treatment for Cannabis Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2009-08","conditions":"Cannabis Dependence","enrollment":15},{"nctId":"NCT00498628","phase":"PHASE2","title":"Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2007-12","conditions":"Alcoholism, Alcohol Abuse","enrollment":224},{"nctId":"NCT01697709","phase":"PHASE2","title":"Quetiapine Pharmacotherapy for Cannabis Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2012-10-01","conditions":"Cannabis Dependence","enrollment":130},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01662297","phase":"PHASE4","title":"Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans","status":"TERMINATED","sponsor":"VA Connecticut Healthcare System","startDate":"2012-07","conditions":"Insomnia, Mental Health Disorder, Substance Use Disorder","enrollment":1},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02562287","phase":"PHASE4","title":"Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-10","conditions":"Bipolar Disorder","enrollment":54},{"nctId":"NCT00183443","phase":"PHASE3","title":"Treatment of Mania Symptoms With Drug Therapy","status":"COMPLETED","sponsor":"Palo Alto Veterans Institute for Research","startDate":"2005-02","conditions":"Bipolar Disorder, Schizophrenia","enrollment":75},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT01727726","phase":"PHASE3","title":"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-12","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2182},{"nctId":"NCT01331304","phase":"PHASE4","title":"Comparative Effectiveness Study for Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-09","conditions":"Bipolar Disorder","enrollment":482},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT01165541","phase":"PHASE2","title":"A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2010-09","conditions":"Alcohol Dependence","enrollment":20},{"nctId":"NCT00156715","phase":"PHASE4","title":"Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2004-03","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorder","enrollment":23},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01971203","phase":"NA","title":"Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2009-09","conditions":"Major Depressive Disorder, Generalized Anxiety Disorder","enrollment":62},{"nctId":"NCT01811459","phase":"PHASE3","title":"Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2013-02","conditions":"Delirium","enrollment":107},{"nctId":"NCT01570907","phase":"NA","title":"Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-06","conditions":"Treatment for Bipolar I Disorder","enrollment":42},{"nctId":"NCT01570959","phase":"NA","title":"Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-04","conditions":"Bipolar I Disorder","enrollment":56},{"nctId":"NCT01570894","phase":"NA","title":"Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-07","conditions":"Bipolar I Disorder","enrollment":42},{"nctId":"NCT01133821","phase":"PHASE4","title":"Acute Psychotherapy for Bipolar II Depression","status":"COMPLETED","sponsor":"Holly Swartz","startDate":"2010-08","conditions":"Bipolar Disorder, Depression","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Seroquel (quetiapine)","genericName":"Seroquel (quetiapine)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}